Medical Imaging Modalities for Prostate Cancer Diagnosis

Prostate cancer, which usually occurs in older men, is the second prevent type of cancer that exists. Approximately 11.2% of men will be diagnosed with prostate cancer at some point during their lifetime. Although it is usually a slowly progressing disease, prostate cancer can sometimes manifest as an aggressive cancer.

The primary way to diagnose the disease is via prostate imaging. This necessity drives its demand in the clinic.

A review by Tooba Khaliq, Rashid Rasheed, Dan Cheng et al, published in Current Medical Imaging Reviews, covers traditional and new imaging methods for screening the prostate gland for the occurrence of neoplasms.[1]

In the review, the authors give special attention to Prostate Specific Membrane Antigen (PSMA), Bombesin (BN) and Androgen Receptor (AR) targeted imaging using Positron Emission Tomography (PET) and Single Positron Emission Computed Tomography (SPECT) based on 99mTc and other radiotracers.

The reviewers conclude that androgen receptor based imaging is the future direction for prostate specific imaging and can be a better way to diagnose prostate cancer using non-steroidal antiandrogen agents.

Reference
[1] Khaliq T, Rasheed R, Cheng D, Kong T, Wang L, Azhar S, Jabeen N, Lu Y, Murtaza G. Past and Present of Imaging Modalities Used for Prostate Cancer Diagnosis: Androgen Receptor Targeted Imaging of Prostate Cancer as a Future Modality for Early, Rapid and Efficient Diagnosis. Current Medical Imaging Reviews | Volume 14 , Issue 6 , 2018 | DOI : 10.2174/1573405613666170718093336


Last Editorial Review: January 2, 2019

Featured Image: Image of cancer woman having support of her family. Courtesy: © 2010 – 2019 Fotolia. Used with permission. Image 1.0: Syrosingopine Courtesy:  © 2010 – 2019 Ciba/Novartis. Used with permission.

Copyright © 2010 – 2019 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine, Oncozine and The Onco’Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.